Advancing novel anesthetics: Pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in Dogs

Anesthesiology

Volumn 121, Issue 6, 2014, Pages 1203-1216

  Campagna, Jason A ^a   Pojasek, Kevin ^b   Grayzel, David ^b   Randle, John ^b   Raines, Douglas E ^c  

^a MEDICINES COMPANY   (United States)

^b Annovation BioPharma Inc   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CYCLOPROPYL METHOXYCARBONYL METOMIDATE; ETOMIDATE; HYPNOTIC AGENT; METOMIDATE; PROPOFOL; UNCLASSIFIED DRUG; HYPNOTIC SEDATIVE AGENT; INTRAVENOUS ANESTHETIC AGENT;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE; DRUG HALF LIFE; DRUG METABOLISM; HYDROCORTISONE BLOOD LEVEL; NONHUMAN; PHARMACODYNAMICS; PROVOCATION TEST; RIGHTING REFLEX; SEDATION; ADRENAL CORTEX; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; AREA UNDER THE CURVE; DOG; DRUG EFFECTS; MALE; MEDICINAL CHEMISTRY; STATISTICAL MODEL;

ADRENAL CORTEX; ANESTHESIA; ANESTHETICS, INTRAVENOUS; ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; CHEMISTRY, PHARMACEUTICAL; DOGS; ETOMIDATE; HYPNOTICS AND SEDATIVES; MALE; MODELS, STATISTICAL; PROPOFOL;

EID: 84914152985     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000416     Document Type: Article

References (44)

1. Forman SA: Clinical and molecular pharmacology of etomidate. Anesthesiology 2011; 114:695-707
2. Ledingham IM,Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet, 1983, 1: 1270.
3. Watt I, Ledingham IM: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984; 39:973-81
4. Kaneda K, Yamashita S, Woo S, Han TH : Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. J Clin Pharmacol 2011; 51:482-91
5. Allolio B, Stuttmann R, Leonhard U, Fischer H, Winkelmann W: Adrenocortical suppression by a single induction dose of etomidate. Klin Wochenschr 1984; 62:1014-7
6. de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW: Etomidate suppresses adrenocortical function by inhibition of 11 β-hydroxylation. J Clin Endocrinol Metab 1984; 59:1143-7
7. Absalom A, Pledger D, Kong A: Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54:861-7
8. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D: Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984; 310:1415-21
9. den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF: One single dose of etomidate negatively influences adrenocortical performance for at least 24 h in children with meningococcal sepsis. Intensive Care Med 2008; 34:163-8
10. Vinclair M, Broux C, Faure P, Brun J, Genty C, Jacquot C, Chabre O, Payen JF: Duration of adrenal inhibition following a single dose of etomidate in critically ill patients. Intensive Care Med 2008; 34:714-9
11. Jackson WL Jr: Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock? A critical appraisal. Chest 2005; 127:1031-8
12. Fengler BT: Should etomidate be used for rapid-sequence intubation induction in critically ill septic patients? Am J Emerg Med 2008; 26:229-32
13. Hildreth AN, Mejia VA, Maxwell RA,Smith PW, Dart BW, Barker DE :Adrenal suppression following a single dose of etomidate for rapid sequence induction: A prospective randomized study. J Trauma 2008; 65: 573-9.
14. Warner KJ, Cuschieri J, Jurkovich GJ, Bulger EM: Single-dose etomidate for rapid sequence intubation may impact outcome after severe injury. J Trauma 2009; 67:45-50
15. E dwin SB, Walker PL: Controversies surrounding the use of etomidate for rapid sequence intubation in patients with suspected sepsis. Ann Pharmacother 2010; 44:1307-13
16. Komatsu R, You J, Mascha EJ, Sessler DI, Kasuya Y, Turan A: Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery. Anesth Analg 2013; 117:1329-37
17. Chan CM, Mitchell AL, Shorr AF: Etomidate is associated with mortality and adrenal insufficiency in sepsis: A meta-Analysis. Crit Care Med 2012; 40:2945-53
18. Albert SG , Ariyan S, Rather A: The effect of etomidate on adrenal function in critical illness: A systematic review. Intensive Care Med 2011; 37:901-10
19. Cotten JF, Husain SS , Forman SA, Miller KW, Kelly EW, Nguyen HH , Raines DE: Methoxycarbonyl-etomidate: A novel rapidly metabolized and ultra-short-Acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009; 111:240-9
20. Cotten JF, Le Ge R, Banacos N, Pejo E, Husain SS , Williams JH, Raines DE: Closed-loop continuous infusions of etomidate and etomidate analogs in rats: A comparative study of dosing and the impact on adrenocortical function. Anesthesiology 2011; 115:764-73
21. Ge RL, Pejo E, Haburcak M, Husain SS , Forman SA, Raines DE: Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite. Anesth Analg ; 2012, 115: 305-8.
22. Ge R, Pejo E, Husain SS , Cotten JF, Raines DE: Electroencephalographic and hypnotic recoveries after brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology ;2012, 117, 1037-43.
23. H usain SS , Pejo E, Ge R, Raines DE: Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action. Anesthesiology; 2012, 117, 1027-36.
24. Pejo E, Ge R, Banacos N, Cotten JF, Husain SS , Raines DE: Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite after continuous infusions of a rapidly metabolized etomidate analog in rats. Anesthesiology 2012; 116:1057-65
25. G e R, Pejo E, Cotten JF, Raines DE: Adrenocortical suppression and recovery after continuous hypnotic infusion: Etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate. Crit Care; 2013, 17: R20.
26. S harma V, McNeill JH: To scale or not to scale: The principles of dose extrapolation. Br J Pharmacol 2009; 157:907-21
27. Mager DE, Woo S, Jusko WJ: Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 2009; 24:16-24
28. Parkinson C, Grasso P: The use of the dog in toxicity tests on pharmaceutical compounds. Hum Exp Toxicol 1993; 12:99-109
29. S mith D, Broadhead C, Descotes G, Fosse R, Hack R, Krauser K, Pfister R, Phillips B, Rabemampianina Y, Sanders J, Sparrow S, Stephan-Gueldner M, Jacobsen SD: Preclinical safety evaluation using nonrodent species: An industry/welfare project to minimize dog use. IL AR J 2002; 43(suppl): S39-42
30. G len JB: Animal studies of the anaesthetic activity of ICI 35 868. Br J Anaesth 1980; 52:731-42
31. Silva A, Campos S., Monteiro J, Venâncio C, Costa B, Guedes de Pinho P, Antunes L: Performance of anesthetic depth indexes in rabbits under propofol anesthesia: Prediction probabilities and concentration-effect relations. Anesthesiology ;2011, 115, 303-314.
32. Perrier D, Gibaldi M: General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci 1982; 71:474-5
33. Meissner K, Avram MJ, Yermolenka V, Francis AM, Blood J, Kharasch ED: Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. Anesthesiology 2013; 119:941-53
34. L iao M, Sonner JM, Husain SS , Miller KW, Jurd R, Rudolph U, Eger EI II : R (+) etomidate and the photoactivable R (+) azietomidate have comparable anesthetic activity in wildtype mice and comparably decreased activity in mice with a N265M point mutation in the ?-Aminobutyric acid receptor β3 subunit. Anesth Analg 2005; 101:131-5
35. S hafer SL : Principles of pharmacokinetics and pharmacodynamics, anesthesiology, Principles and Practice of Anesthesiology. Edited by Longnecker DE, Tinker JH, Morgan GE . St. Louis, Mosby, 1998, pp 1159-210
36. Nxumalo JL, Teranaka M, Schenk WG Jr: Hepatic blood flow measurement III . Total hepatic blood flow measured by ICG clearance and electromagnetic flowmeters in a canine septic shock model. Ann Surg 1978; 187:299-302
37. Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10:1093-5
38. Fraser R, Watt I, Gray CE, Ledingham IM, Lever AF: The effect of etomidate on adrenocortical function in dogs before and during hemorrhagic shock. Endocrinology 1984; 115:2266-70
39. Kruse-Elliott KT, Swanson CR, Aucoin DP: Effects of etomidate on adrenocortical function in canine surgical patients. Am J Vet Res 1987; 48:1098-100
40. Dodam JR, Kruse-Elliott KT, Aucoin DP, Swanson CR: Duration of etomidate-induced adrenocortical suppression during surgery in dogs. Am J Vet Res 1990; 51:786-8
41. L ambert A, Mitchell R, Robertson WR: Effect of propofol, thiopentone and etomidate on adrenal steroidogenesis in vitro. Br J Anaesth 1985; 57:505-8
42. Crozier TA, Beck D, Wuttke W, Kettler D: [Relation of the inhibition of cortisol synthesis in vivo to plasma etomidate concentrations]. Anaesthesist 1988; 37:337-9
43. Van Hamme MJ, Ghoneim MM, Ambre JJ: Pharmacokinetics of etomidate, a new intravenous anesthetic. Anesthesiology 1978; 49:274-7
44. H ermann DJ, Egan TD, Muir KT: Influence of arteriovenous sampling on remifentanil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1999; 65:511-8